menu
    • menu
    [{"orgOrder":0,"company":"Cingulate Therapeutics","sponsor":"Societal CDMO","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Agreement","leadProduct":"Dexmethylphenidate","moa":"Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Cingulate Therapeutics \/ Cingulate Therapeutics, LLC","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics \/ Cingulate Therapeutics, LLC"},{"orgOrder":0,"company":"Cingulate Therapeutics","sponsor":"Indegene","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Agreement","leadProduct":"Dexmethylphenidate","moa":"Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Cingulate Therapeutics \/ Cingulate Therapeutics, LLC","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics \/ Cingulate Therapeutics, LLC"},{"orgOrder":0,"company":"Cingulate Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Norepinephrine transporter","graph1":"Undisclosed","graph2":"Phase I","graph3":"Cingulate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cingulate Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cingulate Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cingulate Therapeutics","sponsor":"Bend Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Partnership","leadProduct":"Dexmethylphenidate","moa":"Dopamine transporter | Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cingulate Therapeutics \/ Cingulate Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics \/ Cingulate Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by Cingulate Therapeutics

    Menu

    Cingulate Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Cingulate Therapeutics

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Cingulate Therapeutics

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dexmethylphenidate

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase III

                            Recipient : Bend Bioscience

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Cingulate Secures Exclusive Manufacturing Partnership with Bend Bio Sciences

                            Details : The agreement aims for the manufacturing of CTx-1301(dexmethylphenidate HCl), the company’s lead asset for the treatment of attention deficit/hyperactivity disorder (ADHD).

                            Product Name : CTx-1301

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            September 17, 2025

                            Lead Product(s) : Dexmethylphenidate

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase III

                            Recipient : Bend Bioscience

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Cingulate Therapeutics

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Cingulate Therapeutics

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dexmethylphenidate

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            In-clinic Crossover Study in Subjects with Two Treatments (Fed vs Fasted)

                            Details : Dexmethylphenidate is a Controlled Substance drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of unspecified medical condition.

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            August 12, 2025

                            Lead Product(s) : Dexmethylphenidate

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Cingulate Therapeutics

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Cingulate Therapeutics

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dexmethylphenidate

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase III

                            Recipient : Indegene

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Cingulate and Indegene Announce Joint Commercialization Agreement for Lead ADHD Candidate CTx-1301

                            Details : Under the agreement, Indegene will provide commercial support for Cingulate’s lead candidate CTx-1301 (dexmethylphenidate), a novel, investigational treatment being developed as a true, once-daily stimulant medication for attention deficit/hyperactivit...

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Undisclosed

                            March 13, 2023

                            Lead Product(s) : Dexmethylphenidate

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase III

                            Recipient : Indegene

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Cingulate Therapeutics

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Cingulate Therapeutics

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dexmethylphenidate

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase III

                            Recipient : Societal CDMO

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Cingulate Announces Agreement with Societal CDMO and Provides Clinical Update

                            Details : Under the agreement, Societal CDMO will manufacture all clinical, registration, and commercial batches of Cingulate’s lead candidate CTx-1301 (dexmethylphenidate), an investigational medication for the treatment of Attention Deficit / Hyperactivity Dis...

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Undisclosed

                            October 24, 2022

                            Lead Product(s) : Dexmethylphenidate

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase III

                            Recipient : Societal CDMO

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth